Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: A reassessment on the basis of 3 independent stage III melanoma cohorts
Source: MDLinx, June 2020
Researchers sought to examine 3 independent data sets to ascertain the survival probabilities of patients with stage III melanoma. Evaluation of 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012 was done in the Central Malignant Melanoma Registry (CMMR). Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were examined as reference cohorts.
